We are live on ! Find out more
BBH icon

VanEck Biotech ETF
BBH

Fund managers haven’t disclosed any holdings of BBH yet.

BBH Hedge Fund Activity: Q1 2026 in Review

112 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2026, worth a combined $123M — down 1.5% from $125M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BBH positions and 12 closed out — a net gain of 4 holders — while 21 added to existing stakes and 25 trimmed.

The largest buyer was Ascent Advisors, opening a new position worth an estimated $11.5M. The largest seller was Morgan Stanley, cutting an estimated $5.03M.

  • 112 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2026, up from 111 in Q4 2025.
  • Funds reported $123M of VanEck Biotech ETF stock for Q1 2026, down 1.5% quarter-over-quarter.
  • 16 funds opened new VanEck Biotech ETF positions in Q1 2026 and 12 closed out, a net change of +4 holders.
  • The largest VanEck Biotech ETF buyer in Q1 2026 was Ascent Advisors, an estimated $11.5M added.
  • The largest VanEck Biotech ETF seller in Q1 2026 was Morgan Stanley, an estimated $5.03M sold.

Based on aggregated 13F filings for Q1 2026.